Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD

53.79  -0.15 (-0.28%)

After market: 53.79 0 (0%)

Fundamental Rating

5

SRPT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. There are concerns on the financial health of SRPT while its profitability can be described as average. SRPT is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

SRPT had positive earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT reported 4 times negative net income.
SRPT had negative operating cash flow in 4 of the past 5 years.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

The Return On Assets of SRPT (5.94%) is better than 94.19% of its industry peers.
The Return On Equity of SRPT (15.40%) is better than 95.77% of its industry peers.
The Return On Invested Capital of SRPT (6.09%) is better than 94.19% of its industry peers.
Industry RankSector Rank
ROA 5.94%
ROE 15.4%
ROIC 6.09%
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With an excellent Profit Margin value of 12.37%, SRPT belongs to the best of the industry, outperforming 95.25% of the companies in the same industry.
SRPT's Operating Margin of 11.47% is amongst the best of the industry. SRPT outperforms 94.19% of its industry peers.
SRPT has a better Gross Margin (83.22%) than 86.09% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
Industry RankSector Rank
OM 11.47%
PM (TTM) 12.37%
GM 83.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SRPT is destroying value.
Compared to 1 year ago, SRPT has more shares outstanding
The number of shares outstanding for SRPT has been increased compared to 5 years ago.
The debt/assets ratio for SRPT has been reduced compared to a year ago.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SRPT has an Altman-Z score of 1.17. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.17, SRPT is doing good in the industry, outperforming 70.25% of the companies in the same industry.
SRPT has a Debt/Equity ratio of 0.74. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
SRPT's Debt to Equity ratio of 0.74 is on the low side compared to the rest of the industry. SRPT is outperformed by 76.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z 1.17
ROIC/WACC0.64
WACC9.51%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.20 indicates that SRPT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.20, SRPT is in line with its industry, outperforming 49.12% of the companies in the same industry.
A Quick Ratio of 3.18 indicates that SRPT has no problem at all paying its short term obligations.
SRPT's Quick ratio of 3.18 is on the low side compared to the rest of the industry. SRPT is outperformed by 60.92% of its industry peers.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 3.18
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 137.25% over the past year.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 52.98%.
The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)137.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%219.15%
Revenue 1Y (TTM)52.98%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%65.94%

3.2 Future

Based on estimates for the next years, SRPT will show a very strong growth in Earnings Per Share. The EPS will grow by 45.47% on average per year.
Based on estimates for the next years, SRPT will show a quite strong growth in Revenue. The Revenue will grow by 15.26% on average per year.
EPS Next Y214.63%
EPS Next 2Y135.85%
EPS Next 3Y87.02%
EPS Next 5Y45.47%
Revenue Next Year65.9%
Revenue Next 2Y42.07%
Revenue Next 3Y29.86%
Revenue Next 5Y15.26%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 23.59, SRPT is valued on the expensive side.
95.42% of the companies in the same industry are more expensive than SRPT, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of SRPT to the average of the S&P500 Index (28.29), we can say SRPT is valued inline with the index average.
The Price/Forward Earnings ratio is 7.50, which indicates a rather cheap valuation of SRPT.
97.89% of the companies in the same industry are more expensive than SRPT, based on the Price/Forward Earnings ratio.
SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.32, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.59
Fwd PE 7.5
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 94.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.57
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SRPT's earnings are expected to grow with 87.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y135.85%
EPS Next 3Y87.02%

More info and screens

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (4/17/2025, 8:00:00 PM)

After market: 53.79 0 (0%)

53.79

-0.15 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners101.88%
Inst Owner Change0.73%
Ins Owners4.36%
Ins Owner Change2.44%
Market Cap5.22B
Analysts82
Price Target172.29 (220.3%)
Short Float %5.54%
Short Ratio5.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)163.14%
Min EPS beat(2)-22.48%
Max EPS beat(2)348.76%
EPS beat(4)3
Avg EPS beat(4)521.38%
Min EPS beat(4)-22.48%
Max EPS beat(4)1173.24%
EPS beat(8)6
Avg EPS beat(8)617.29%
EPS beat(12)8
Avg EPS beat(12)394.49%
EPS beat(16)9
Avg EPS beat(16)294.13%
Revenue beat(2)2
Avg Revenue beat(2)7.38%
Min Revenue beat(2)2.86%
Max Revenue beat(2)11.9%
Revenue beat(4)3
Avg Revenue beat(4)3.24%
Min Revenue beat(4)-9.09%
Max Revenue beat(4)11.9%
Revenue beat(8)6
Avg Revenue beat(8)3.63%
Revenue beat(12)9
Avg Revenue beat(12)2.59%
Revenue beat(16)11
Avg Revenue beat(16)2.32%
PT rev (1m)-6.11%
PT rev (3m)-8.74%
EPS NQ rev (1m)-148.29%
EPS NQ rev (3m)-113.75%
EPS NY rev (1m)-38.25%
EPS NY rev (3m)-37.94%
Revenue NQ rev (1m)-1.1%
Revenue NQ rev (3m)-2.68%
Revenue NY rev (1m)-0.78%
Revenue NY rev (3m)-0.88%
Valuation
Industry RankSector Rank
PE 23.59
Fwd PE 7.5
P/S 2.74
P/FCF N/A
P/OCF N/A
P/B 3.42
P/tB 3.48
EV/EBITDA 18.57
EPS(TTM)2.28
EY4.24%
EPS(NY)7.17
Fwd EY13.34%
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS19.6
BVpS15.75
TBVpS15.47
PEG (NY)0.11
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.94%
ROE 15.4%
ROCE 6.75%
ROIC 6.09%
ROICexc 10.48%
ROICexgc 10.64%
OM 11.47%
PM (TTM) 12.37%
GM 83.22%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA 4.45
Cap/Depr 389.56%
Cap/Sales 7.73%
Interest Coverage 13.75
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 3.18
Altman-Z 1.17
F-Score5
WACC9.51%
ROIC/WACC0.64
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)137.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%219.15%
EPS Next Y214.63%
EPS Next 2Y135.85%
EPS Next 3Y87.02%
EPS Next 5Y45.47%
Revenue 1Y (TTM)52.98%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%65.94%
Revenue Next Year65.9%
Revenue Next 2Y42.07%
Revenue Next 3Y29.86%
Revenue Next 5Y15.26%
EBIT growth 1Y181.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year315.82%
EBIT Next 3Y126%
EBIT Next 5Y45.96%
FCF growth 1Y40.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.92%
OCF growth 3YN/A
OCF growth 5YN/A